# A Study of HB0025 Plus Nab-paclitaxel as First Line Therapy for TNBC

Source: https://onco.cc/trials/nct07376629/  
OnCo record `nct07376629` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of nab-paclitaxel in triple-negative breast cancer, run by Huabo Biopharm Co., Ltd., now recruiting.

## Summary

A Study of HB0025 Plus Nab-paclitaxel as First Line Therapy for TNBC is a phase 2, interventional study registered as NCT07376629 by Huabo Biopharm Co., Ltd., with a registry enrolment figure of 60 participants, started 2025-08-14 and due to reach its primary completion in 2027-01-15. Interventions recorded: HB0025 20 mg/kg plus nab-paclitaxel; HB0025 10 mg/kg plus nab-paclitaxel. Conditions listed: TNBC. Triple-negative eligibility wording from the registry: "Metastatic or locally advanced, histologically documented TNBC (absence of HER2, ER, and PR expression)". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Tags: ctgov-ingest; tnbc-deep-dive
- Registry id: NCT07376629
- Phase: 2
- Setting: A Phase II Study of HB0025 in Combination With Nab-Paclitaxel as First Line Therapy for Unresectable, Locally Advanced or Metastatic Triple-negative Breast Cancer.
- Sponsor: Huabo Biopharm Co., Ltd.
- Enrolled: 60

## Sources

- ClinicalTrials.gov NCT07376629: https://clinicaltrials.gov/study/NCT07376629

## Connected records

- cancers: [Metastatic triple-negative breast cancer](https://onco.cc/cancers/tnbc-metastatic/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/)
- drugs: [Nab-paclitaxel](https://onco.cc/drugs/nab-paclitaxel/)
- terms: [Triple-negative breast cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/tnbc-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07376629.json